CRIS Current Research Information System

BARTOLETTI, DANIELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.443
AS - Asia 1.409
EU - Europa 785
Continente sconosciuto - Info sul continente non disponibili 94
AF - Africa 92
SA - Sud America 76
OC - Oceania 3
Totale 3.902
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.397
SG - Singapore 425
VN - Vietnam 351
CN - Cina 336
IT - Italia 151
DE - Germania 122
SE - Svezia 118
GB - Regno Unito 97
HK - Hong Kong 78
IN - India 70
FR - Francia 59
BR - Brasile 56
IE - Irlanda 45
RU - Federazione Russa 43
NL - Olanda 37
FI - Finlandia 36
CI - Costa d'Avorio 35
KR - Corea 34
CA - Canada 29
TG - Togo 22
JP - Giappone 18
BD - Bangladesh 14
ZA - Sudafrica 13
CH - Svizzera 11
ID - Indonesia 11
PL - Polonia 11
JO - Giordania 10
PH - Filippine 10
TH - Thailandia 10
BE - Belgio 9
TR - Turchia 9
TW - Taiwan 9
UA - Ucraina 9
AT - Austria 7
BG - Bulgaria 7
MX - Messico 7
AR - Argentina 5
CO - Colombia 5
EC - Ecuador 5
EE - Estonia 5
PK - Pakistan 5
NG - Nigeria 4
SA - Arabia Saudita 4
TN - Tunisia 4
AU - Australia 3
ET - Etiopia 3
HR - Croazia 3
IQ - Iraq 3
JM - Giamaica 3
MA - Marocco 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AZ - Azerbaigian 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
EG - Egitto 2
ES - Italia 2
LT - Lituania 2
RO - Romania 2
UY - Uruguay 2
AO - Angola 1
BB - Barbados 1
BS - Bahamas 1
CY - Cipro 1
DK - Danimarca 1
DZ - Algeria 1
GA - Gabon 1
GE - Georgia 1
GF - Guiana Francese 1
HU - Ungheria 1
KE - Kenya 1
KY - Cayman, isole 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MG - Madagascar 1
MK - Macedonia 1
MY - Malesia 1
NI - Nicaragua 1
NP - Nepal 1
PE - Perù 1
PY - Paraguay 1
RS - Serbia 1
SC - Seychelles 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
UZ - Uzbekistan 1
Totale 3.808
Salva come PNG Salva come JPEG
Città #
Singapore 317
Ashburn 186
Chandler 121
San Jose 113
Hanoi 91
Ho Chi Minh City 77
Hong Kong 71
Southend 69
Fairfield 64
Santa Clara 55
Hefei 54
Beijing 46
Dublin 45
Dallas 44
Los Angeles 38
Princeton 38
Abidjan 35
Dong Ket 32
Houston 30
Helsinki 29
Woodbridge 29
Seoul 27
Boardman 26
Bologna 26
Seattle 25
Wilmington 25
Council Bluffs 24
New York 24
Cambridge 22
Lomé 22
Milan 22
Hyderabad 21
Munich 21
Lauterbourg 20
Ann Arbor 17
Redmond 15
Nanjing 14
Buffalo 13
Frankfurt am Main 13
São Paulo 13
Tokyo 13
Bremen 12
Da Nang 12
Berlin 11
Amman 10
Westminster 10
Brussels 9
Haiphong 9
Bern 8
Chicago 8
Johannesburg 8
London 8
Nuremberg 8
Shanghai 8
Toronto 8
Turin 8
Warsaw 8
Des Moines 7
Jakarta 7
Sofia 7
Guangzhou 6
Orem 6
Phoenix 6
Redondo Beach 6
Rome 6
San Francisco 6
Shenyang 6
Amsterdam 5
Bengaluru 5
Boydton 5
Brooklyn 5
City of London 5
Columbus 5
Lappeenranta 5
Montreal 5
Paris 5
Redwood City 5
Saint Petersburg 5
San Diego 5
Abeokuta 4
Atlanta 4
Biên Hòa 4
Boston 4
Bình Phước 4
Changchun 4
Fort Lauderdale 4
Hải Dương 4
Migliarino 4
Norwalk 4
Shijiazhuang 4
Stockholm 4
The Dalles 4
Vienna 4
Wayne 4
Wenzhou 4
Addis Ababa 3
Bari 3
Can Tho 3
Chennai 3
Dhaka 3
Totale 2.334
Salva come PNG Salva come JPEG
Nome #
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 232
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 229
Spleen and Liver Fibrosis Is Associated to Treatment Response and Prognosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms 227
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 215
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis 199
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 180
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 159
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 155
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 155
Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients 150
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis 149
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. 144
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 141
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 139
Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies 133
The diagnostic role of next generation sequencing in uncovering isolated splenomegaly: A case report 132
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 130
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis 127
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia 127
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib 122
Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study 113
Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients’ satisfaction 107
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 98
Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity 93
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 90
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome 88
null 68
Totale 3.902
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.945
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.945
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022344 0 13 13 33 25 18 8 32 16 31 91 64
2022/2023478 35 58 30 63 44 48 12 28 97 14 26 23
2023/2024173 9 38 18 18 14 22 2 14 4 15 8 11
2024/2025667 59 59 59 64 70 34 42 48 8 63 43 118
2025/20261.659 149 122 150 119 164 94 161 99 387 123 40 51
2026/2027147 138 9 0 0 0 0 0 0 0 0 0 0
Totale 3.902